BAIT
FGFR3
ACH, CD333, CEK2, HSFGFR3EX, JTK4
fibroblast growth factor receptor 3
GO Process (27)
GO Function (4)
GO Component (3)
Gene Ontology Biological Process
- Fc-epsilon receptor signaling pathway [TAS]
- JAK-STAT cascade [TAS]
- bone maturation [ISS]
- bone mineralization [ISS]
- bone morphogenesis [ISS, TAS]
- chondrocyte differentiation [TAS]
- chondrocyte proliferation [TAS]
- endochondral bone growth [TAS]
- endochondral ossification [TAS]
- epidermal growth factor receptor signaling pathway [TAS]
- fibroblast growth factor receptor apoptotic signaling pathway [IMP]
- fibroblast growth factor receptor signaling pathway [IDA, IGI, TAS]
- innate immune response [TAS]
- insulin receptor signaling pathway [TAS]
- negative regulation of developmental growth [ISS]
- neurotrophin TRK receptor signaling pathway [TAS]
- peptidyl-tyrosine phosphorylation [IDA]
- phosphatidylinositol-mediated signaling [TAS]
- positive regulation of ERK1 and ERK2 cascade [IMP]
- positive regulation of MAPK cascade [IMP]
- positive regulation of cell proliferation [IGI, IMP]
- positive regulation of phosphatidylinositol 3-kinase activity [IMP, TAS]
- positive regulation of phospholipase activity [IMP]
- positive regulation of tyrosine phosphorylation of Stat1 protein [IMP]
- positive regulation of tyrosine phosphorylation of Stat3 protein [IMP]
- protein autophosphorylation [IDA]
- skeletal system development [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
ANXA3
ANX3
annexin A3
GO Process (6)
GO Function (2)
GO Component (6)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment.
Systematic testing of existing drugs and their combinations is an attractive strategy to exploit approved drugs for repurposing and identifying the best actionable treatment options. To expedite the search among many possible drug combinations, we designed a combinatorial CRISPR-Cas9 screen to inhibit druggable targets. Coblockade of the N-methyl-d-aspartate receptor (NMDAR) with targets of first-line kinase inhibitors reduced hepatocellular carcinoma (HCC) ... [more]
Cancer Res Dec. 15, 2020; 81(24);6219-6232 [Pubmed: 34666996]
Throughput
- Low Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507) [viability (PATO:0000169)]
Additional Notes
- CRISPR GI screen
- Cell Line: MHCC97L HCC
- Experimental Setup: Timecourse
- GIST: A-phenotypic negative genetic interaction
- Library: Targeted CRISPRn library
- Significance Threshold: mean log2 ratios of <-0.51 at P<0.05
Curated By
- BioGRID